COPDC-FINDNCT06008145
COPD Case Finding In Nottingham and District: C-FIND COPD A Pilot Study
An observational study of COPD, run by Nottingham University Hospitals NHS Trust at 1 site in United Kingdom.
Trial summary
The Targeted Lung Health Check (TLHC) is currently being rolled out in many regions of the United Kingdom and has just started in Nottingham. The same cohort of people are also at high risk for Chronic Obstructive Pulmonary Disease (COPD), a lung condition often caused by smoking and leading to breathlessness and… Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- COPD
- How many people
- 568 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 21 Sep 2023to 31 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The Targeted Lung Health Check (THLC) cohort are a population that are at high risk for COPD, a lung condition often caused by smoking. This same population will be invited to undertake breathing test in order to early diagnose COPD.
Who may be able to join
- Smoking history - either compatible with TLHC (current or ex-smoker who are high risk based on lung cancer risk scores) or if self-presenting >10 pack years (current or ex)
- Able to provide full informed consent.
Who cannot join
- People currently undergoing active investigation or treatment for cancer
- Unable to provide informed consent
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Nottingham University Hospitals NHS Trust
Nottingham, Nottinghamshire, NG5 1PB
About this study
The Targeted Lung Health Check (TLHC) is currently being rolled out in many regions of the United Kingdom and has just started in Nottingham. The same cohort of people are also at high risk for Chronic Obstructive Pulmonary Disease (COPD), a lung condition often caused by smoking and leading to breathlessness and cough. This study aims to provide pilot evidence of the role of breathing tests in those who have had a Computerised Tomography (CT) scan, in order to early diagnose COPD. Currently, at diagnosis, many patients have lost 30-40% of lung function already, which is not reversible.
This study will use the Nottingham University Hospitals Trust Mobile Research Unit. The unit will follow the CT scanner route 2-3 weeks later, and people who have had a CT scan will be invited for breathing tests. Participants will also collect further information on potential treatment options for people diagnosed with COPD earlier -including smoking cessation, symptom management and general health advice (vaccinations, diet, activity and managing infections). There is also an optional blood test.
Read more
The study aims are to determine the uptake and acceptability of breathing tests in patients at high risk of COPD, and if a community based approach co-locating with TLHC can increase uptake.
A qualitative sub-study has been added to assess the opportunities or barriers for people being invited for a COPD diagnosis visit in the community. This sub-study will have a recruitment target of 20 participants. It will involve transcribed interviews. This will help determine the accessibility of the mobile research unit in use for this study.
Read the detailed description
Ever smokers, aged between 55 to 74 years are invited for a telephone risk assessment. Those who are high risk (based on validated lung cancer risk scores, which incorporate a number of variables, including age and smoking intensity) are then sequentially invited for a CT scan in a certain locality of Nottingham as part of the TLHC. As the programme is introduced the number of invites per month will increase from 500 to 1800. It is anticipated that 40 to 45% of those will take up the invite and have a CT scan. At the time of their CT scan all smokers will be offered smoking cessation.
The clinical pathway incorporates that the CT scans will be reported by Heart Lung Health , with responsible clinician - Dr O'Dowd. Patients identified as having cancer or high likelihood will be approached and commenced on a cancer diagnostic pathway. This study addresses people who are not entering this pathway.
Two-three weeks after the CT scan, the clinical team will invite people to attend for a research study to assess lung health if they have symptoms of cough, breathlessness or 2 or more courses antibiotics in the last 15 months. No further reminder will be sent. The investigators will not excluding people with COPD already and will not turn away high-risk people who self-present even if not had a CT.
The invite will include mention of when the mobile unit is open and in their locality, what the visit consists of and that participants are free to come down at a convenient time. A telephone number and e-mail will be provided if somebody contacts the investigators and would prefer to be seen in a standard research unit - an appointment will be provided. The letter will remind participants that this cannot cover broader medical issues or emergencies, where usual clinical advice should be sought.
Following informed consent, the following will occur by trained clinical research practitioners and under the support of a research nurse.
- Questionnaires:
- Symptom scores and information on tobacco smoking / other exposures, past medical history, medication
- COPD Assessment Test (CAT) Quality of Life score
- Medical Research Council (MRC) breathlessness score
- Exacerbation frequency
- EQ5D - Health Status
- Observations:
- Oximetry for heart rate and oxygen saturations
- Height
- Weight
- Blood pressure
- Postbronchodilator spirometry - salbutamol delivered by trained staff.
- Forced Oscillation Technique (FOT)- a non-clinically used breathing test but might have a role in early detection.
- Approach for future research and store research data obtained here / review medical records for future medicines.
- Invite to provide a blood sample and nasal swab for early markers of COPD - optional and currently of no clinical relevance.
Those with clinical evidence of COPD will be given information by a registered Health Care professional trained to do so on:
- COPD and what it is.
- Need for immunisations.
- General health education, self-management and tobacco cessation where indicated.
- Whether further review at the surgery is required.
- Clinical information will be fed back to primary care surgery and uploaded onto medical health records, such as SystemOne. The participant will have consented to this.
The investigators will seek feedback from participants and subsequently from the primary care clinicians.
A qualitative sub-study has been added to assess the opportunities or barriers for people being invited for a COPD diagnosis visit in the community. This sub-study will have a recruitment target of 20 participants. It will involve transcribed interviews. This will help determine the accessibility of the mobile research unit in use for this study.
- Conditions
- COPD
- Keywords
- COPD
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of people who take up the invite to attend for a C-FIND visit.
0-100%
Measured: 1.5 years
Secondary outcomes (17)
Proportion diagnosed with COPD
0-100%
Measured: 1.5 years
CAT COPD Quality of Life Score
Questionnaire. Wellbeing and daily life questions, scored 0-40 points, lower better
Measured: 1 day
MRC breathlessness score
Questionnaire, self reported breathlessness grade 1-5, lower better
Measured: 1 day
Exacerbation Frequency
0-12/year
Measured: 1 day
EQ-5D-5L - Health Status
Questionnaire. Self reported health scale 0-100. Greater better
Measured: 1 day
Oximetry for oxygen saturations
75-100% Oxygen saturation
Measured: 1 day
Height
Participant height in metres - range 1.2-2.0m
Measured: 1 day
Weight
participant weight in Kg - range 35-180Kg
Measured: 1 day
BMI
12-60g/m2
Measured: 1 day
Blood pressure diastolic
40-120mmHg
Measured: 1 day
Post bronchodilator Spirometry
Forced Expired Volume (FEV)% - range 10-140% predicted
Measured: 1 day
FOT-R (Resistance)
cmH2O.s/l
Measured: 1 day
FOT-X (reactance)
cmH2O.s/l
Measured: 1 day
FOT-AX (area of reactance)
cmH2O/L
Measured: 1 day
FOT-Fres (resonant Frequency)
Hz
Measured: 1 day
Blood pressure -systolic
75-230mmHg
Measured: 1 day
What are the opportunities or barriers for people being invited for a COPD diagnosis visit in the community
To assess the barriers and opportunities presented by the use of the mobile research unit
Measured: From enrolment to the end of study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Aug 2023
- Study start21 Sep 2023
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 568 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nottingham University Hospitals NHS Trust
- Sponsor type
- University, hospital or other
- Collaborators
- University of Nottingham
- Responsible party
- Sponsor
- Investigators
- Charlotte Bolton, MD, PhD, Principal investigator, Nottingham University Hospitals NHS Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06008145
- Sponsor's protocol ID
- 23RM005
- Acronym
- C-FIND
- Status last verified
- Dec 2025
- First submitted
- 20 Jul 2023
- Last updated
- 19 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COPD Case Finding In Nottingham and District: C-FIND COPD A Pilot Study
- ClinicalTrials.gov ID
- NCT06008145
- Acronym / sponsor ID
- C-FIND / 23RM005
- Conditions
- COPD
- Keywords
- COPD
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 568 participants (actual)
- Lead sponsor
- Nottingham University Hospitals NHS TrustUniversity, hospital or other
- Collaborators
- University of Nottingham
- Study start
- 21 Sep 2023 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 23 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Targeted Lung Health Check (TLHC) is currently being rolled out in many regions of the United Kingdom and has just started in Nottingham. The same cohort of people are also at high risk for Chronic Obstructive Pulmonary Disease (COPD), a lung condition often caused by smoking and leading to breathlessness and cough. This study aims to provide pilot evidence of the role of breathing tests in those who have had a Computerised Tomography (CT) scan, in order to early diagnose COPD. Currently, at diagnosis, many patients have lost 30-40% of lung function already, which is not reversible.
This study will use the Nottingham University Hospitals Trust Mobile Research Unit. The unit will follow the CT scanner route 2-3 weeks later, and people who have had a CT scan will be invited for breathing tests. Participants will also collect further information on potential treatment options for people diagnosed with COPD earlier -including smoking cessation, symptom management and general health advice (vaccinations, diet, activity and managing infections). There is also an optional blood test.
The study aims are to determine the uptake and acceptability of breathing tests in patients at high risk of COPD, and if a community based approach co-locating with TLHC can increase uptake.
A qualitative sub-study has been added to assess the opportunities or barriers for people being invited for a COPD diagnosis visit in the community. This sub-study will have a recruitment target of 20 participants. It will involve transcribed interviews. This will help determine the accessibility of the mobile research unit in use for this study.
Detailed description
Ever smokers, aged between 55 to 74 years are invited for a telephone risk assessment. Those who are high risk (based on validated lung cancer risk scores, which incorporate a number of variables, including age and smoking intensity) are then sequentially invited for a CT scan in a certain locality of Nottingham as part of the TLHC. As the programme is introduced the number of invites per month will increase from 500 to 1800. It is anticipated that 40 to 45% of those will take up the invite and have a CT scan. At the time of their CT scan all smokers will be offered smoking cessation.
The clinical pathway incorporates that the CT scans will be reported by Heart Lung Health , with responsible clinician - Dr O'Dowd. Patients identified as having cancer or high likelihood will be approached and commenced on a cancer diagnostic pathway. This study addresses people who are not entering this pathway.
Two-three weeks after the CT scan, the clinical team will invite people to attend for a research study to assess lung health if they have symptoms of cough, breathlessness or 2 or more courses antibiotics in the last 15 months. No further reminder will be sent. The investigators will not excluding people with COPD already and will not turn away high-risk people who self-present even if not had a CT.
The invite will include mention of when the mobile unit is open and in their locality, what the visit consists of and that participants are free to come down at a convenient time. A telephone number and e-mail will be provided if somebody contacts the investigators and would prefer to be seen in a standard research unit - an appointment will be provided. The letter will remind participants that this cannot cover broader medical issues or emergencies, where usual clinical advice should be sought.
Following informed consent, the following will occur by trained clinical research practitioners and under the support of a research nurse.
- Questionnaires:
- Symptom scores and information on tobacco smoking / other exposures, past medical history, medication
- COPD Assessment Test (CAT) Quality of Life score
- Medical Research Council (MRC) breathlessness score
- Exacerbation frequency
- EQ5D - Health Status
- Observations:
- Oximetry for heart rate and oxygen saturations
- Height
- Weight
- Blood pressure
- Postbronchodilator spirometry - salbutamol delivered by trained staff.
- Forced Oscillation Technique (FOT)- a non-clinically used breathing test but might have a role in early detection.
- Approach for future research and store research data obtained here / review medical records for future medicines.
- Invite to provide a blood sample and nasal swab for early markers of COPD - optional and currently of no clinical relevance.
Those with clinical evidence of COPD will be given information by a registered Health Care professional trained to do so on:
- COPD and what it is.
- Need for immunisations.
- General health education, self-management and tobacco cessation where indicated.
- Whether further review at the surgery is required.
- Clinical information will be fed back to primary care surgery and uploaded onto medical health records, such as SystemOne. The participant will have consented to this.
The investigators will seek feedback from participants and subsequently from the primary care clinicians.
A qualitative sub-study has been added to assess the opportunities or barriers for people being invited for a COPD diagnosis visit in the community. This sub-study will have a recruitment target of 20 participants. It will involve transcribed interviews. This will help determine the accessibility of the mobile research unit in use for this study.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The Targeted Lung Health Check (THLC) cohort are a population that are at high risk for COPD, a lung condition often caused by smoking. This same population will be invited to undertake breathing test in order to early diagnose COPD.
Key inclusion criteria (2 listed)
- Smoking history - either compatible with TLHC (current or ex-smoker who are high risk based on lung cancer risk scores) or if self-presenting >10 pack years (current or ex)
- Able to provide full informed consent.
Key exclusion criteria (2 listed)
- People currently undergoing active investigation or treatment for cancer
- Unable to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Proportion of people who take up the invite to attend for a C-FIND visit.
Time frame: 1.5 years
0-100%
17 secondary outcomes
Proportion diagnosed with COPD
Time frame: 1.5 years
CAT COPD Quality of Life Score
Time frame: 1 day
MRC breathlessness score
Time frame: 1 day
Exacerbation Frequency
Time frame: 1 day
EQ-5D-5L - Health Status
Time frame: 1 day
Oximetry for oxygen saturations
Time frame: 1 day
Height
Time frame: 1 day
Weight
Time frame: 1 day
BMI
Time frame: 1 day
Blood pressure diastolic
Time frame: 1 day
Post bronchodilator Spirometry
Time frame: 1 day
FOT-R (Resistance)
Time frame: 1 day
FOT-X (reactance)
Time frame: 1 day
FOT-AX (area of reactance)
Time frame: 1 day
FOT-Fres (resonant Frequency)
Time frame: 1 day
Blood pressure -systolic
Time frame: 1 day
What are the opportunities or barriers for people being invited for a COPD diagnosis visit in the community
Time frame: From enrolment to the end of study
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
Related trials for COPD
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
RecruitingPhase 2
Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD
Chronic Obstructive Pulmonary Disease
Recruiting
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
COPD, Chronic Obstructive Pulmonary Disease
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Recruiting
Comparison of Several Oxygenation Targets With Different Oxygen Interfaces - Impact on Oxygen Flow Rates
Oxygen Toxicity, COPD Bronchitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charlotte Bolton, MD, PhD principal investigator
Nottingham University Hospitals NHS Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COPD, run by Nottingham University Hospitals NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of people who take up the invite to attend for a C-FIND visit. (time frame: 1.5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.